Evolve Business Intelligence has published a half-cooked research report on the Global Endometriosis Treatment Market, 2021–2030. The global Endometriosis Treatment market is projected to exhibit a CAGR of around 3.4% during the forecast period of 2022 to 2030.
Evolve Business Intelligence has recognized the following companies as the key players in the global Endometriosis Treatment Market: Astra Zeneca Plc., Eli Lilly and Company, Astellas Pharma, Bayer AG, Meditrina Pharmaceuticals, Abbvie, PfizerInc, Takeda Pharmaceutica, and Neurocrine Biosciences Inc.
Market Highlights
The global Endometriosis Treatment market is projected to be valued at $2.332 Billion by 2030, recording a CAGR of around 3.4% during the forecast period. Endometriosis is a condition that affects 176 million women worldwide. It occurs when tissue similar to the lining of the uterus (endometrium) grows outside of the bright red uterine cavity. Symptoms of Endometriosis can vary from person to person but may include pelvic cramping, excessive bleeding, and infertility. Many factors have led to the expansion in the endometriosis market such as the increasing prevalence of endometriosis, diagnosis methods and treatment options, and greater awareness among people.
The Endometriosis Treatment market has been severely impacted by the spread of the Coronavirus pandemic. The spread of the disease to other countries, along with the lack of pharmaceutical-grade competition and government funding has led to a dramatic decrease in the Endometriosis Treatment market. The loss of revenue attributed to the Coronavirus pandemic has caused an overall decline in the global Endometriosis Treatment market. This decline has contributed to a major drop in demand for Endometriosis Treatment and a lack of new investment opportunities for companies.
Segmental Analysis
The global Endometriosis Treatment market has been segmented based on the Drug type, Treatment Type, Distribution Channel, and region.
By Drug Type, the Endometriosis Treatment market is segmented based on Progestin, Gonadotropins Releasing Hormone Agonists, Oral Contraceptive Pills, Non-Steroidal Anti-Inflammatory Drugs, and Others. The Oral Contraceptive Pills segment dominates the market. Oral contraceptives are preferred to other methods in cases where there are no contraindications because they are effective in preventing the prevalence of pelvic pain and endometriosis lesions.
Based on Treatment Type, the Endometriosis Treatment market is segmented based on Pain Management and Hormonal Therapies. The Hormonal Therapiessegment is anticipated to hold the largest market. High treatment efficacy and acceptance without too much risk are expected to lead to a greater number of patients using hormonal therapy. Hormonal Therapy has been proven to have enhanced effectiveness and minimal risk of breast cancer.
Based on Distribution Channel, the Endometriosis Treatment market is segmented based on Hospital Pharmacies, E-Pharmacies, Retail Pharmacies, and Others. Patients in Hospitals and Retail pharmacies collectively make up the majority of the market. Hospitals are seeing an increased demand for endometriosis treatment due to a large patient base and because they’re close to home and convenient.
Access Full Report: https://evolvebi.com/product/global-endometriosis-treatment-market-market-analysis-and-global-forecast-2022-2030-with-covid-impact-analysis/
Regional Analysis
The Endometriosis Treatment market is divided into six regions: North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa. The North American region is projected to dominate the global Endometriosis Treatment market due to the increased awareness about women’s health and the increased spending power on healthcare. Moreover, with the presence of major players in the region, the market is expected to grow at a rapid pace. However, due to increased government expenditure on R&D activities in developing countries, Asia-Pacific is expected to outstrip all other areas by clocking the highest CAGR. The Endometriosis Treatment business in Europe has been consistently growing with a robust drug pipeline. Latin America and Africa are also expected to grow at a rapid pace in the forecast period.